- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cellectis (ALCLS)
Track the Cellectis share price today and view real-time ALCLS share price data, including charts, technicals, and key financials. View the ALCLS premarket stock price ahead of the market session or assess the after hours quote. Explore ALCLS stock price movements, trading volume, and market activity across the EPA exchange.
What Is the Cellectis Stock Price Today?
The Cellectis stock price today is 2.84.
What Is the Stock Symbol for Cellectis?
The stock symbol for Cellectis is ""ALCLS.""
What Stock Exchange Does Cellectis Trade On?
Cellectis is listed and trades on the Paris stock exchange.
Is Cellectis a Good Stock to Buy?
Determining whether Cellectis or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALCLS quote. (ISIN: FR0010425595)
What Is the Cellectis Stock Price Today?
The Cellectis stock price today is 2.84.
What Is the Stock Symbol for Cellectis?
The stock symbol for Cellectis is ""ALCLS.""
What Stock Exchange Does Cellectis Trade On?
Cellectis is listed and trades on the Paris stock exchange.
Is Cellectis a Good Stock to Buy?
Determining whether Cellectis or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALCLS quote. (ISIN: FR0010425595)
2.84
-0.11(-3.73%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.82
2.92
52 wk Range
1.01
4.84
ALCLS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.822.92
52 wk Range
1.014.84
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALCLS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
6.50
Upside
+128.87%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Cellectis Earnings Call Summary for Q2/2025
- Q2 2025 EPS of -$0.2075 missed forecasts by 13.51%, despite revenue of $15.73M beating expectations by 56.52%
- Stock fell 13.3% after-hours; cash runway extends to H2 2027, ensuring financial stability for ongoing R&D initiatives
- Advancements in product pipeline, including UCART22 and AstraZeneca collaborations; pivotal trials planned for 2026
- CEO highlights transformative potential of product candidates and technologies for hard-to-treat cancers and genetic disorders
- Ongoing arbitration with Servier presents potential risks; company expresses confidence in favorable outcome
Last Updated: 05/08/2025, 11:56 pm
Read Full TranscriptCompare ALCLS to Peers and Sector
Metrics to compare | ALCLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALCLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.7x | −1.3x | −0.5x | |
PEG Ratio | 0.06 | −0.04 | 0.00 | |
Price/Book | 3.3x | 1.9x | 2.6x | |
Price / LTM Sales | 3.1x | 4.5x | 3.1x | |
Upside (Analyst Target) | 120.3% | 61.4% | 55.9% | |
Fair Value Upside | Unlock | 15.8% | 7.4% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.50
(+128.87% Upside)
Earnings
Latest Release
19/03/2026
EPS / Forecast
-0.23 / -0.25
Revenue / Forecast
10.57M / 9.71M
People Also Watch
FAQ
What Is the Cellectis (ALCLS) Stock Price Today?
The Cellectis stock price today is 2.84 EUR.
What Stock Exchange Does Cellectis Trade On?
Cellectis is listed and trades on the Paris Stock Exchange.
What Is the Stock Symbol for Cellectis?
The stock symbol for Cellectis is "ALCLS."
What Is the Cellectis Market Cap?
As of today, Cellectis market cap is 206.88M EUR.
What Is Cellectis's Earnings Per Share (TTM)?
The Cellectis EPS (TTM) is -0.67.
When Is the Next Cellectis Earnings Date?
Cellectis will release its next earnings report on 30/04/2026.
From a Technical Analysis Perspective, Is ALCLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Cellectis Stock Split?
Cellectis has split 0 times.
How Many Employees Does Cellectis Have?
Cellectis has 219 employees.
What is the current trading status of Cellectis (ALCLS)?
As of 26/03/2026, Cellectis (ALCLS) is trading at a price of 2.84 EUR, with a previous close of 2.95 EUR. The stock has fluctuated within a day range of 2.82 EUR to 2.92 EUR, while its 52-week range spans from 1.01 EUR to 4.84 EUR.
What Is Cellectis (ALCLS) Price Target According to Analysts?
The average 12-month price target for Cellectis is 6.50 EUR, with a high estimate of 6.5 EUR and a low estimate of 6.5 EUR. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +128.87% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.